BioCentury
ARTICLE | Clinical News

Eslicarbazepine meets in pair of Phase III seizure trials

September 18, 2013 1:01 AM UTC

The Sunovion Pharmaceuticals Inc. subsidiary of Dainippon Sumitomo Pharma Co. Ltd. (Tokyo:4506; Osaka:4506) said once-daily eslicarbazepine as monotherapy met the primary endpoint in each of a pair of identical Phase III trials to treat partial-onset seizures in adults with epilepsy. The voltage-gated sodium and T-type calcium channel blocker significantly reduced the proportion of patients with worsening seizure control at 16 weeks post-titration vs. historical controls. The double-blind trials enrolled a total of 365 epileptic patients who were not well controlled by antiepileptic drugs. ...